Lilly chief John Lechleiter called for a shift in thinking on healthcare reform “from an emphasis on cost to an understanding of value … and from thinking in terms of the broad population to focusing on meeting the needs of individual patients.” The emphasis on cost is misguided, he said, because it can increase health spending over time by slowing or blocking the flow of new medicines to market.